Insider Selling: Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $86,063.20 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Traci Umberger sold 3,580 shares of the firm’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $24.04, for a total value of $86,063.20. Following the completion of the sale, the insider directly owned 195,825 shares in the company, valued at $4,707,633. The trade was a 1.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Price Performance

KMTS traded up $0.21 during midday trading on Thursday, reaching $25.27. 184,867 shares of the company’s stock traded hands, compared to its average volume of 393,651. Kestra Medical Technologies, Ltd. has a 52 week low of $14.10 and a 52 week high of $30.00. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16. The firm has a fifty day moving average of $22.86 and a two-hundred day moving average of $22.54.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%.The business had revenue of $28.64 million during the quarter. On average, equities analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Wall Street Zen downgraded shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Oppenheimer initiated coverage on shares of Kestra Medical Technologies in a research note on Tuesday, July 21st. They set a “market perform” rating on the stock. BTIG Research boosted their price target on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. The Goldman Sachs Group decreased their price target on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. Finally, Wolfe Research set a $30.00 price objective on shares of Kestra Medical Technologies in a report on Wednesday, July 15th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $27.83.

Hedge Funds Weigh In On Kestra Medical Technologies

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC bought a new position in Kestra Medical Technologies during the 1st quarter valued at approximately $11,036,000. Woodline Partners LP purchased a new position in shares of Kestra Medical Technologies in the 1st quarter worth about $2,510,000. Jane Street Group LLC bought a new position in Kestra Medical Technologies in the 1st quarter worth about $756,000. Geode Capital Management LLC grew its position in Kestra Medical Technologies by 718.5% during the 2nd quarter. Geode Capital Management LLC now owns 325,326 shares of the company’s stock valued at $5,395,000 after purchasing an additional 285,579 shares during the last quarter. Finally, JPMorgan Chase & Co. bought a new stake in Kestra Medical Technologies during the 2nd quarter valued at about $256,000.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.